Drug Profile
Cladribine - CHORD Therapeutics
Alternative Names: CRD-1Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator CHORD Therapeutics
- Class Antineoplastics; Antipsoriatics; Deoxyadenosines; Purine nucleosides; Ribonucleosides; Skin disorder therapies; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Myasthenia gravis
- No development reported Neuromuscular disorders
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for preclinical development in Neuromuscular-disorders in Switzerland (PO)
- 15 Oct 2020 Preclinical trials in Myasthenia gravis in Switzerland (PO) (CHORD Therapeutics website, October 2020)
- 13 Oct 2020 Preclinical development is still ongoing for Neurological disorders in Switzerland